🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06939400
Starting soon Observational

Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence

NCT06939400 · tracked via the Priya Life Science China tracker
Sponsor
Zhejiang Provincial People's Hospital
Phase
Observational
Started
2025-06-01
Last updated
2025-04-22

Condition(s) studied

Glioblastoma Multiforme (GBM)

Investigational drug(s) / intervention(s)

Photodynamic therapy (PDT)GBM patients recevied traditional treatment options

Photodynamic therapy (PDT): GBM patients recevied surgical combination photodynamic therapy

GBM patients recevied traditional treatment options: GBM patients recevied traditional treatment options (including surgery combined with radiotherapy and chemotherapy)

Study summary

GBM patients receiving PDT treatment (50 cases,surgery combined with photodynamic therapy) and traditional treatment (50 cases,traditional surgery) in our hospital and partner hospitals were collected. The prognosis was analyzed by comparing with the control group from multiple perspectives such as image evaluation, imaging effect, Karnofsky score, median survival time and survival rate.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: Pathologically confirmed primary focal GBM; Recurrent GBM(single or satellite lesions); Multiple (multiple germinal centers)GBM. Exclusion Criteria: * Photosensitizer allergy. * Severe coagulation disorder. * Patients with severe cardiovascular and cerebrovascular diseases, especially patients in the acute stage. * Multiple organ failure, end-stage patients. ⑤ Pregnant women: Photofrin is considered a class C pregnancy risk (toxic, non-teratogenic) drug with non-dialysis properties. Non-gbm diagnosis: Patients with other types of brain tumors or diseases. 7 Do not agree to informed consent: patients who are unwilling to sign informed consent or do not agree to participate in the study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Zhejiang Provincial People's Hospital Hangzhou Zhejiang

More Zhejiang Provincial People's Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06939400 on ClinicalTrials.gov ↗ ← All trials in China